Concert Pharmaceuticals Names Jesper Høiland to its Board of Directors

LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;–Concert
Pharmaceuticals, Inc. (NASDAQ:CNCE) announced today that Jesper
Høiland has been appointed to its Board of Directors and will serve as a
member of its Compensation Committee, effective immediately.

“We are delighted to welcome Jesper to our Board of Directors,” said
Roger Tung, Ph.D., President and Chief Executive Officer of Concert
Pharmaceuticals. “He is a highly accomplished executive with current
management experience as President and CEO of Radius Health, a
biopharmaceutical company, and previously served as President and
Executive Vice President, Novo Nordisk Inc. USA, where his expertise in
product launches and management were instrumental in growing Novo to
become the 15^th largest pharmaceutical company worldwide.
Jesper also brings extensive pharmaceutical commercialization expertise,
which will broaden and strengthen the overall skills of our Board as we
advance our pipeline of innovative medicines towards regulatory
approval.”

“Concert’s pipeline has significant potential to meaningfully impact
patients affected by serious diseases that have unmet medical needs,”
said Mr. Høiland. “I am excited to join the Board and look forward to
sharing my insights and experiences as Concert’s product candidates,
CTP-543 for alopecia areata and CTP-692 for schizophrenia, advance
through development toward commercialization.”

Mr. Høiland is an industry veteran with more than 30 years of experience
in the biopharmaceutical industry across numerous senior leadership
roles, geographies and therapeutic areas. As President and Chief
Executive Officer of Radius Health, Inc., Mr. Høiland successfully
launched Radius’ first commercial product, TYMLOS™. Prior to joining
Radius, Mr. Høiland served as President and Executive Vice President of
Novo Nordisk. During his more than 20-year tenure at Novo Nordisk, Mr.
Høiland held multiple global roles of increasing responsibility,
including leading its International Operations which spanned 150
countries. Mr. Høiland is a member of the Board of Directors of LEO
Pharma and from 2014-2016 was a Board member of PhRMA, the
Pharmaceutical Research and Manufacturers of America. Mr. Høiland
received his M.Sc. in Management from Copenhagen Business School in
Denmark.

About Concert

Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy.
Concert’s pipeline of
innovative medicines targets autoimmune diseases and central nervous
systems (CNS) disorders. For more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
All other trademarks are those of their respective owners.

Contacts

Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
(781)
674-5284
[email protected]

Kathryn
Morris (media)
The Yates Network
(914) 204-6412
[email protected]